Neptune Files ITC Complaint Against Competitors Aker, Enzymotec, Rimfrost, Olympic and Others

Neptune Files ITC Complaint Against Competitors Aker, Enzymotec, Rimfrost,
Olympic and Others

LAVAL, Quebec, Jan. 30, 2013 (GLOBE NEWSWIRE) -- Neptune Technologies &
Bioressources Inc. ("Neptune") (Nasdaq.NEPT) (TSX:NTB) announces that it has
filed a complaint under Section 337 of the US Tariff Act of 1930 (the
"Complaint") with the United States International Trade Commission (the "ITC")
alleging that Aker BioMarine AS, Aker BioMarine Antarctic USA, Inc., Aker
BioMarine Antarctic AS, Enzymotec Limited, Enzymotec USA, Inc., Olympic
Seafood AS, Olympic Biotec Ltd., Rimfrost USA, LLC, Bioriginal Food & Science
Corp. and Avoca, Inc., a division of Pharmachem Laboratories Inc. (the
"Respondents") are engaging in unfair trade practices by, at least, the
importation, sale for importation, and sale after importation of certain
krill-based products, namely krill paste and krill oils, that directly or
indirectly infringe one or more claims of Neptune's U.S. Patent No. 8,278,351
("the '351 Patent").

"Neptune's patent estate reflects its position as the pioneer and market
leader in the field. The filing of the Complaint is consistent with our
philosophy that infringing competitors must be held accountable for their
actions," said Mr. Henri Harland, Neptune's CEO and President. "This approach
will enhance our business position as the leader and the innovator in this

Neptune is seeking an order prohibiting the Respondents, their subsidiaries,
related companies and agents from engaging in the importation, sale for
importation, marketing and/or advertising, distribution, offering for sale,
sale, sale after importation, or other transfer within the United States of
certain krill-based products that infringe one or more claims of the '351
Patent. Neptune expects that the ITC investigation will formally commence
within the next month or so, and that the case will take a total of about 15
to 18 months to conclude.

"The ITC is one of the fastest means for judicial resolution of a patent
dispute in the United States and it has the power to issue broad and severe
remedies," added Mr. Harland. "When a company infringes our patents, without
our permission or a license, we owe it to our shareholders and investors to
protect the patents through every means available to us," he concluded.

About Neptune Technologies & Bioressources Inc.

Neptune is a biotechnology company engaged primarily in the development and
commercialization of marine-derived omega-3 polyunsaturated fatty acids, or
PUFAs. Neptune has a patented process of extracting oils from Antarctic krill,
which omega-3 PUFAs are then principally sold as bulk oil to Neptune's
distributors who commercialize them under their private label primarily in the
U.S., European and Asian neutraceutical markets. Neptune's lead products,
Neptune Krill Oil (NKO®) and ECOKRILL Oil (EKO™), generally come in capsule
form and serve as a dietary supplement to consumers.

Through its subsidiaries Acasti Pharma Inc. ("Acasti") (TSX-V:APO)
(Nasdaq:ACST) and NeuroBioPharm Inc. ("NeuroBioPharm"), in which Neptune
respectively holds 57% and 96% of the voting rights, Neptune is also pursuing
opportunities in the medical food and prescription drug markets. Acasti and
NeuroBioPharm respectively focus on the research and development of safe and
therapeutically effective compounds for highly prevalent atherosclerotic
conditions, such as cardiometabolic disorders and cardiovascular diseases, and
for neurodegenerative and inflammation related conditions. Acasti's lead
prescription drug candidate is CaPre®, a purified high omega-3 phospholipid
concentrate derived from Neptune krill oil being developed to address the
prevention and treatment of cardiometabolic disorders, including
hypertriglyceridemia, which is characterized by abnormally high levels of

Forward Looking Statements

Certain statements included in this press release may be considered
forward-looking information within the meaning of Canadian securities laws and
forward-looking statements within the meaning of U.S. federal securities laws,
both of which we refer to as forward-looking statements. Such statements
involve known and unknown risks, uncertainties and other factors that may
cause results, performance or achievements to be materially different from
those implied by such statements, and therefore these statements should not be
read as guarantees of future performance or results. All forward-looking
statements are based on Neptune's current beliefs as well as assumptions made
by and information currently available to Neptune and relate to, among other
things, Neptune's strategy, strategic goals, research and development
activities, research and clinical testing outcome, future operations, future
financial position, future revenues/results, projected costs, prospects and
plans and objectives of management.

Readers are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release. Due to
risks and uncertainties, including the risks and uncertainties identified by
Neptune in its amended and restated annual information form dated September
11, 2012, in its press release announcing an action plan to resume operations
and supply customers dated November 26, 2012 and in its other public
securities filings available at and,
actual events may differ materially from current expectations. Except as
required by law, Neptune disclaims any intention or obligation to update or
revise any forward-looking statements.

CONTACT: Neptune Contact:
         Neptune Technologies & Bioressources Inc.
         Andre Godin, CFO
         Howard Group Contact:
         Dave Burwell
         (888) 221-0915
Press spacebar to pause and continue. Press esc to stop.